{"id":143,"date":"2013-08-30T19:38:16","date_gmt":"2013-08-30T18:38:16","guid":{"rendered":"http:\/\/www.novacos-law.com\/en\/?p=143"},"modified":"2016-03-30T19:39:49","modified_gmt":"2016-03-30T18:39:49","slug":"die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer","status":"publish","type":"post","link":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/","title":{"rendered":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer"},"content":{"rendered":"<p>The article discusses new requirements for pharmaceutical companies related to reporting obligations for post-market surveillance studies in Germany<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The article discusses new requirements for pharmaceutical companies related to reporting obligations for post-market surveillance studies in Germany<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-143","post","type-post","status-publish","format-standard","hentry","category-publications"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.9 - aioseo.com -->\n\t<meta name=\"description\" content=\"The article discusses new requirements for pharmaceutical companies related to reporting obligations for post-market surveillance studies in Germany\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Maria Heil\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.9\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#article\",\"name\":\"Die Neuregelung des \\u00a7 67 Abs. 6 AMG \\u2013 Erweiterte Transparentpflichten f\\u00fcr den pharmazeutischen Unternehmer | NOVACOS\",\"headline\":\"Die Neuregelung des \\u00a7 67 Abs. 6 AMG \\u2013 Erweiterte Transparentpflichten f\\u00fcr den pharmazeutischen Unternehmer\",\"author\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/author\\\/mheil\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/#organization\"},\"datePublished\":\"2013-08-30T19:38:16+02:00\",\"dateModified\":\"2016-03-30T19:39:49+02:00\",\"inLanguage\":\"en-GB\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#webpage\"},\"articleSection\":\"Publications\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.novacos-law.com\\\/en\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/category\\\/publications\\\/#listItem\",\"name\":\"Publications\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/category\\\/publications\\\/#listItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/category\\\/publications\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#listItem\",\"name\":\"Die Neuregelung des \\u00a7 67 Abs. 6 AMG \\u2013 Erweiterte Transparentpflichten f\\u00fcr den pharmazeutischen Unternehmer\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#listItem\",\"position\":3,\"name\":\"Die Neuregelung des \\u00a7 67 Abs. 6 AMG \\u2013 Erweiterte Transparentpflichten f\\u00fcr den pharmazeutischen Unternehmer\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/category\\\/publications\\\/#listItem\",\"name\":\"Publications\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/#organization\",\"name\":\"Novacos Law\",\"description\":\"Heil \\u2022 H\\u00fcbner \\u2022 Natz \\u2022 Oeben Partnerschaft mbB\",\"url\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/author\\\/mheil\\\/#author\",\"url\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/author\\\/mheil\\\/\",\"name\":\"Maria Heil\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2b4b63a50b72e9a07e921c072b756cdeea932196118f4d8a2f4bfa94dceaaacf?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Maria Heil\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#webpage\",\"url\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/\",\"name\":\"Die Neuregelung des \\u00a7 67 Abs. 6 AMG \\u2013 Erweiterte Transparentpflichten f\\u00fcr den pharmazeutischen Unternehmer | NOVACOS\",\"description\":\"The article discusses new requirements for pharmaceutical companies related to reporting obligations for post-market surveillance studies in Germany\",\"inLanguage\":\"en-GB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/2013\\\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/author\\\/mheil\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/author\\\/mheil\\\/#author\"},\"datePublished\":\"2013-08-30T19:38:16+02:00\",\"dateModified\":\"2016-03-30T19:39:49+02:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/\",\"name\":\"Novacos Law\",\"description\":\"Heil \\u2022 H\\u00fcbner \\u2022 Natz \\u2022 Oeben Partnerschaft mbB\",\"inLanguage\":\"en-GB\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.novacos-law.com\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer | NOVACOS","description":"The article discusses new requirements for pharmaceutical companies related to reporting obligations for post-market surveillance studies in Germany","canonical_url":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#article","name":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer | NOVACOS","headline":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer","author":{"@id":"https:\/\/www.novacos-law.com\/en\/author\/mheil\/#author"},"publisher":{"@id":"https:\/\/www.novacos-law.com\/en\/#organization"},"datePublished":"2013-08-30T19:38:16+02:00","dateModified":"2016-03-30T19:39:49+02:00","inLanguage":"en-GB","mainEntityOfPage":{"@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#webpage"},"isPartOf":{"@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#webpage"},"articleSection":"Publications"},{"@type":"BreadcrumbList","@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en#listItem","position":1,"name":"Home","item":"https:\/\/www.novacos-law.com\/en","nextItem":{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en\/category\/publications\/#listItem","name":"Publications"}},{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en\/category\/publications\/#listItem","position":2,"name":"Publications","item":"https:\/\/www.novacos-law.com\/en\/category\/publications\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#listItem","name":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#listItem","position":3,"name":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer","previousItem":{"@type":"ListItem","@id":"https:\/\/www.novacos-law.com\/en\/category\/publications\/#listItem","name":"Publications"}}]},{"@type":"Organization","@id":"https:\/\/www.novacos-law.com\/en\/#organization","name":"Novacos Law","description":"Heil \u2022 H\u00fcbner \u2022 Natz \u2022 Oeben Partnerschaft mbB","url":"https:\/\/www.novacos-law.com\/en\/"},{"@type":"Person","@id":"https:\/\/www.novacos-law.com\/en\/author\/mheil\/#author","url":"https:\/\/www.novacos-law.com\/en\/author\/mheil\/","name":"Maria Heil","image":{"@type":"ImageObject","@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/2b4b63a50b72e9a07e921c072b756cdeea932196118f4d8a2f4bfa94dceaaacf?s=96&d=mm&r=g","width":96,"height":96,"caption":"Maria Heil"}},{"@type":"WebPage","@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#webpage","url":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/","name":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer | NOVACOS","description":"The article discusses new requirements for pharmaceutical companies related to reporting obligations for post-market surveillance studies in Germany","inLanguage":"en-GB","isPartOf":{"@id":"https:\/\/www.novacos-law.com\/en\/#website"},"breadcrumb":{"@id":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/#breadcrumblist"},"author":{"@id":"https:\/\/www.novacos-law.com\/en\/author\/mheil\/#author"},"creator":{"@id":"https:\/\/www.novacos-law.com\/en\/author\/mheil\/#author"},"datePublished":"2013-08-30T19:38:16+02:00","dateModified":"2016-03-30T19:39:49+02:00"},{"@type":"WebSite","@id":"https:\/\/www.novacos-law.com\/en\/#website","url":"https:\/\/www.novacos-law.com\/en\/","name":"Novacos Law","description":"Heil \u2022 H\u00fcbner \u2022 Natz \u2022 Oeben Partnerschaft mbB","inLanguage":"en-GB","publisher":{"@id":"https:\/\/www.novacos-law.com\/en\/#organization"}}]}},"aioseo_meta_data":{"post_id":"143","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"WebPage","isEnabled":true},"graphs":[]},"schema_type":null,"schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"location":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2020-12-21 12:16:30","updated":"2025-07-25 08:39:58","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.novacos-law.com\/en\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.novacos-law.com\/en\/category\/publications\/\" title=\"Publications\">Publications<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tDie Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.novacos-law.com\/en"},{"label":"Publications","link":"https:\/\/www.novacos-law.com\/en\/category\/publications\/"},{"label":"Die Neuregelung des \u00a7 67 Abs. 6 AMG \u2013 Erweiterte Transparentpflichten f\u00fcr den pharmazeutischen Unternehmer","link":"https:\/\/www.novacos-law.com\/en\/2013\/die-neuregelung-des-67-abs-6-amg-erweiterte-transparentpflichten-fuer-den-pharmazeutischen-unternehmer\/"}],"_links":{"self":[{"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/posts\/143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/comments?post=143"}],"version-history":[{"count":0,"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/posts\/143\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/media?parent=143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/categories?post=143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.novacos-law.com\/en\/wp-json\/wp\/v2\/tags?post=143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}